Zobrazeno 1 - 10
of 532
pro vyhledávání: '"Alexander, Drilon"'
Autor:
Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones, Kevin Nusser, Catherine Z. Beach, Guilherme Harada, Alexander Drilon, Monika A. Davare
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-11 (2024)
Abstract ROS1 tyrosine kinase inhibitors (TKIs) are highly effective in ROS1-positive non-small cell lung cancer, but resistance remains a challenge. We investigated the activity of various TKIs against wildtype and mutant ROS1, focusing on the emerg
Externí odkaz:
https://doaj.org/article/a2f0d426aed049d5ae3fab63257a9869
Autor:
Rajat Thawani, Matteo Repetto, Clare Keddy, Katelyn Nicholson, Kristen Jones, Kevin Nusser, Catherine Z. Beach, Guilherme Harada, Alexander Drilon, Monika A. Davare
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/31196ad66dfb436eb7493219d57ee85d
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100606- (2023)
The emergence of spontaneous nonmalignant chylous effusions during treatment with various tyrosine kinase inhibitors (TKIs) has been previously described; however, there have been no prior reports for alectinib. Herein, we report a case of symptomati
Externí odkaz:
https://doaj.org/article/304b7209d46e4b4fb52cce4a67dfebc0
Autor:
Yonina R. Murciano-Goroff, Alison M. Schram, Ezra Y. Rosen, Helen Won, Yixiao Gong, Anne Marie Noronha, Yelena Y. Janjigian, Zsofia K. Stadler, Jason C. Chang, Soo-Ryum Yang, Diana Mandelker, Kenneth Offit, Michael F. Berger, Mark T. A. Donoghue, Chaitanya Bandlamudi, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Mutations in BRCA1/2 are associated with a homologous recombination deficiency phenotype in BRCA-associated cancers. Reversion mutations can restore BRCA1/2 function and result in treatment resistance in these cancer-types. Here, the authors show tha
Externí odkaz:
https://doaj.org/article/c02201f79842463bb00562d13b866e18
Autor:
Jonathan W. Goldman, Lynette M. Sholl, Sanja Dacic, Michael C. Fishbein, Yonina R. Murciano-Goroff, Ravi Rajaram, Sylwia Szymczak, Anna M. Szpurka, Bo H. Chao, Alexander Drilon
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The LIBRETTO-001 trial demonstrated the activity of the selective rearrangement during transfection (RET) inhibitor selpercatinib in advanced RET fusion-positive non-small cell lung cancer (NSCLC) and resulted in the drug’s approval for this indica
Externí odkaz:
https://doaj.org/article/ff2adc6f3eaf4f15b17c63e038b1aa62
Autor:
Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco, Victoria Robinson, Richard A. Ferraro, Sherri Z. Millis, Anita Krishnan, Jessica Lee, Steven Attia, Wassim Abida, Alexander Drilon, Ping Chi, Sandra P. D’ Angelo, Mark A. Dickson, Mary Lou Keohan, Ciara M. Kelly, Mark Agulnik, Sant P. Chawla, Edwin Choy, Rashmi Chugh, Christian F. Meyer, Parvathi A. Myer, Jessica L. Moore, Ross A. Okimoto, Raphael E. Pollock, Vinod Ravi, Arun S. Singh, Neeta Somaiah, Andrew J. Wagner, John H. Healey, Garrett M. Frampton, Jeffrey M. Venstrom, Jeffrey S. Ross, Marc Ladanyi, Samuel Singer, Murray F. Brennan, Gary K. Schwartz, Alexander J. Lazar, David M. Thomas, Robert G. Maki, William D. Tap, Siraj M. Ali, Dexter X. Jin
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Comprehensive molecular profiles are required to understand and treat sarcomas, which comprise more than 70 different subtypes. Here, the authors profile the genomic landscape of 7494 sarcomas across 44 histologies using targeted panel sequencing and
Externí odkaz:
https://doaj.org/article/ded28dd2538e4114ba7de3e78b153f38
Autor:
James C. H. Yang, Marcia S. Brose, Gilberto Castro, Edward S. Kim, Ulrik N. Lassen, Serge Leyvraz, Alberto Pappo, Fernando López-Ríos, John A. Reeves, Marc Fellous, Frédérique Penault-Llorca, Erin R. Rudzinski, Ghazaleh Tabatabai, Gilles Vassal, Alexander Drilon, Jonathan Trent
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors. Larotrectinib is a first-in-class, highly sel
Externí odkaz:
https://doaj.org/article/d03b60bd6de0450a90283154c262afe5
Autor:
Rafal Dziadziuszko, Tiffany Hung, Kun Wang, Voleak Choeurng, Alexander Drilon, Robert C. Doebele, Fabrice Barlesi, Charlie Wu, Lucas Dennis, Joel Skoletsky, Ryan Woodhouse, Meijuan Li, Ching‐Wei Chang, Brian Simmons, Todd Riehl, Timothy R. Wilson
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 2000-2014 (2022)
Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer. FoundationOne® Liquid CDx (F1L CDx), a
Externí odkaz:
https://doaj.org/article/70c5cd67899f40a68e40335c1c0b149a
Autor:
Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
Publikováno v:
Cancer Medicine, Vol 11, Iss 8, Pp 1796-1804 (2022)
Abstract Purpose The phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on‐target adverse effects (AEs) of PI3K/AKT inhibitors. As several P
Externí odkaz:
https://doaj.org/article/6261ca0f91da4aafad9291fcc66547c9
Autor:
Ezra Y. Rosen, Helen H. Won, Youyun Zheng, Emiliano Cocco, Duygu Selcuklu, Yixiao Gong, Noah D. Friedman, Ino de Bruijn, Onur Sumer, Craig M. Bielski, Casey Savin, Caitlin Bourque, Christina Falcon, Nikeysha Clarke, Xiaohong Jing, Fanli Meng, Catherine Zimel, Sophie Shifman, Srusthi Kittane, Fan Wu, Marc Ladanyi, Kevin Ebata, Jennifer Kherani, Barbara J. Brandhuber, James Fagin, Eric J. Sherman, Natasha Rekhtman, Michael F. Berger, Maurizio Scaltriti, David M. Hyman, Barry S. Taylor, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
The results of the phase 1/2 LIBRETTO-001 clinical trial has recently established the efficacy of the RET inhibitor selpercatinib in RET-driven cancers. Here, the authors characterize the molecular determinants of response and resistance in 72 LIBRET
Externí odkaz:
https://doaj.org/article/c9aadc1f6bbc44acba731c2a7dcb7aef